Vaishnaw Akshay
President of R&D at SRRK; Officer at ALNY
- Sold, on record
- $57.3M
- Dollars the filings state
- Form 4 sales
- 35
- Latest Apr 16, 2026
- Form 144 notices
- 2
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ALNYUnusualFeb 10, 2023 2023
Sold 38,044 shares at $215.97 ($8.2M)
Vaishnaw Akshay, President
Sold 71.8% of holdings ($11.4M position)14,970 shares left4.4x usual sizeFiling
- 2 Form 4 sale ALNYNo planApr 27, 2023 +76 days
Sold 2,392 shares at $194.59 ($465k)
Vaishnaw Akshay, President
No 10b5-1 planSold 11.8% of holdings ($3.9M position)17,890 shares left0.2x usual sizeFiling
- 3 Form 4 sale ALNYNo planAug 4, 2023 +99 days
Sold 4,057 shares at $185.85 ($754k)
Vaishnaw Akshay, President
No 10b5-1 planSold 15.1% of holdings ($5M position)22,774 shares left0.6x usual sizeFiling
- 4 Form 144 notice ALNYNoticeDec 11, 2023 +129 days
Filed to sell 10,832 shares ($1.8M)
Vaishnaw Akshay, Officer
10b5-1 plan3.1x usual sizeFiling
- 5 Form 144 notice SRRKNoticeMay 29, 2025 +535 days
Filed to sell 6,750 shares ($200k)
Vaishnaw Akshay, Director
10b5-1 planFirst sale on recordFiling
- 6 Form 4 sale SRRKRoutineMay 29, 2025 same day
Sold 6,750 shares at $29.72 ($201k)
Vaishnaw Akshay, President of R&D
10b5-1 planSold 1.1% of holdings ($18.5M position)616,205 shares leftFirst sale on recordFollows a Form 144Filing
- 7 Form 4 sale SRRKNo planJan 13, 2026 +229 days
Sold 20,438 shares at $42.70 ($873k)
Vaishnaw Akshay, President of R&D
No 10b5-1 planSold 3.3% of holdings ($26.3M position)595,767 shares leftFiling
- 8 Form 4 sale SRRKNo planApr 16, 2026 +93 days
Sold 12,246 shares at $49.57 ($607k)
Vaishnaw Akshay, President of R&D
No 10b5-1 planSold 1.9% of holdings ($31.9M position)630,542 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (37)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | Apr 20, 2026 | SRRK | President of R&D | Form 4 sale | 12,246 | $607k | 1.9% | No plan | SEC |
| Jan 13, 2026 | Jan 15, 2026 | SRRK | President of R&D | Form 4 sale | 20,438 | $873k | 3.3% | No plan | SEC |
| May 29, 2025 | May 30, 2025 | SRRK | President of R&D | Form 4 sale | 6,750 | $201k | 1.1% | Routine | SEC |
| May 29, 2025 | May 29, 2025 | SRRK | Director | Form 144 notice | 6,750 | $200k | Notice | SEC | |
| Dec 11, 2023 | Dec 11, 2023 | ALNY | Officer | Form 144 notice | 10,832 | $1.8M | Notice | SEC | |
| Aug 4, 2023 | Aug 7, 2023 | ALNY | President | Form 4 sale | 4,057 | $754k | 15.1% | No plan | SEC |
| Apr 27, 2023 | Apr 28, 2023 | ALNY | President | Form 4 sale | 2,392 | $465k | 11.8% | No plan | SEC |
| Feb 10, 2023 | Feb 14, 2023 | ALNY | President | Form 4 sale | 38,044 | $8.2M | 71.8% | Unusual | SEC |
| Dec 23, 2021 | Dec 23, 2021 | ALNY | President, R&D | Form 4 sale | 2,879 | $550k | 20.4% | Plan not stated | SEC |
| Aug 9, 2021 | Aug 11, 2021 | ALNY | President, R&D | Form 4 sale | 10,834 | $2.2M | 49.1% | Unusual | SEC |
| Jun 18, 2021 | Jun 22, 2021 | ALNY | President, R&D | Form 4 sale | 14,708 | $2.6M | 56.7% | Unusual | SEC |
| Apr 21, 2021 | Apr 21, 2021 | ALNY | President, R&D | Form 4 sale | 6,438 | $884k | 31.3% | Unusual | SEC |
| Sep 29, 2020 | Oct 1, 2020 | ALNY | President, R&D | Form 4 sale | 971 | $136k | 6.4% | Plan not stated | SEC |
| Jun 22, 2020 | Jun 24, 2020 | ALNY | President, R&D | Form 4 sale | 970 | $147k | 6.4% | Plan not stated | SEC |
| Apr 20, 2020 | Apr 22, 2020 | ALNY | President, R&D | Form 4 sale | 21,971 | $3.1M | 60.9% | Unusual | SEC |
| Feb 7, 2020 | Feb 11, 2020 | ALNY | President, R&D | Form 4 sale | 23,708 | $3M | 67.9% | Unusual | SEC |
| Mar 14, 2018 | Mar 16, 2018 | ALNY | President, R&D | Form 4 sale | 88,554 | $12.7M | 88.8% | Unusual | SEC |
| Oct 30, 2017 | Nov 1, 2017 | ALNY | EVP, R&D | Form 4 sale | 33,666 | $4.1M | 74.5% | Unusual | SEC |
| May 23, 2017 | May 25, 2017 | ALNY | EVP, R&D | Form 4 sale | 11,000 | $825k | 51.7% | Unusual | SEC |
| May 15, 2017 | May 17, 2017 | ALNY | SVP, R&D | Form 4 sale | 43,750 | $2.8M | 80.9% | Unusual | SEC |
| Nov 30, 2016 | Dec 2, 2016 | ALNY | EVP, R&D, CMO | Form 4 sale | 29,165 | $1.3M | 83.5% | Unusual | SEC |
| Jun 16, 2015 | Jun 18, 2015 | ALNY | EVP, R&D, CMO | Form 4 sale | 8,750 | $1.1M | 100.0% | Unusual | SEC |
| Mar 17, 2015 | Mar 19, 2015 | ALNY | EVP, R&D, CMO | Form 4 sale | 8,750 | $1M | 100.0% | Unusual | SEC |
| Dec 16, 2014 | Dec 16, 2014 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 10,626 | $995k | 100.0% | Unusual | SEC |
| Sep 16, 2014 | Sep 17, 2014 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 10,625 | $766k | 100.0% | Unusual | SEC |
| Jun 17, 2014 | Jun 19, 2014 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 10,625 | $742k | 100.0% | Unusual | SEC |
| Mar 18, 2014 | Mar 20, 2014 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 32,769 | $2.4M | 100.0% | Unusual | SEC |
| Jan 24, 2014 | Jan 27, 2014 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 7,890 | $677k | 100.0% | Unusual | SEC |
| Dec 17, 2013 | Dec 18, 2013 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 33,480 | $2M | 72.7% | Unusual | SEC |
| Sep 10, 2013 | Sep 12, 2013 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 6,250 | $359k | 33.2% | Unusual | SEC |
| Jun 11, 2013 | Jun 13, 2013 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 15,000 | $466k | 54.4% | Unusual | SEC |
| Mar 11, 2013 | Mar 11, 2013 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 6,250 | $153k | 33.2% | Unusual | SEC |
| Dec 12, 2012 | Dec 12, 2012 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 14,777 | $271k | 54.0% | Unusual | SEC |
| Dec 4, 2012 | Dec 6, 2012 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 2,400 | $41k | 16.0% | Plan not stated | SEC |
| Nov 30, 2012 | Dec 4, 2012 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 2,823 | $48k | 18.3% | Plan not stated | SEC |
| Sep 12, 2012 | Sep 12, 2012 | ALNY | EVP, Chief Medical Officer | Form 4 sale | 6,250 | $119k | 33.2% | Unusual | SEC |
| Jul 16, 2012 | Jul 18, 2012 | ALNY | SVP, Chief Medical Officer | Form 4 sale | 36,250 | $689k | 74.2% | Unusual | SEC |